Therefore, these studies suggested that KLF12 might function as a potential therapeutic target via regulating ISG15 expression for inhibition of CSC phenotype in the treatment of cisplatin‐resistant ovarian cancer. Here, ISG15 is linked to ovarian carcinoma.